pyridoxamine and Disease Models, Animal
pyridoxamine has been researched along with Disease Models, Animal in 11 studies
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
Research Excerpts
Excerpt | Relevance | Reference |
---|---|---|
" In the current manuscript, we studied the effect of pyridoxamine (PM) on protein glycation, oxidative stress, interleukin-1α (IL-1α), IL-6, C-reactive protein (CRP), gene expression of tumour necrosis factor-α (TNF-α) and transforming growth factor-β1 (TGF-β1) in relation to microalbuminuria and kidney functions in a model of alloxan-induced diabetic rats." | 7.79 | Pyridoxamine, an inhibitor of protein glycation, in relation to microalbuminuria and proinflammatory cytokines in experimental diabetic nephropathy. ( Elseweidy, MM; Elswefy, SE; Younis, NN; Zaghloul, MS, 2013) |
" In the current manuscript, we studied the effect of pyridoxamine (PM) on protein glycation, oxidative stress, interleukin-1α (IL-1α), IL-6, C-reactive protein (CRP), gene expression of tumour necrosis factor-α (TNF-α) and transforming growth factor-β1 (TGF-β1) in relation to microalbuminuria and kidney functions in a model of alloxan-induced diabetic rats." | 3.79 | Pyridoxamine, an inhibitor of protein glycation, in relation to microalbuminuria and proinflammatory cytokines in experimental diabetic nephropathy. ( Elseweidy, MM; Elswefy, SE; Younis, NN; Zaghloul, MS, 2013) |
" Metabolic profile, NO bioavailability and vascular oxidative stress, AGE and Nrf2 levels were also assessed." | 1.46 | The Sulforaphane and pyridoxamine supplementation normalize endothelial dysfunction associated with type 2 diabetes. ( Crisóstomo, J; Fernandes, R; Pereira, A; Seiça, RM; Sena, CM, 2017) |
"A mouse model for diabetic nephropathy that encompasses the salient features of this disease in the kidney is not available." | 1.34 | Renal fibrosis and glomerulosclerosis in a new mouse model of diabetic nephropathy and its regression by bone morphogenic protein-7 and advanced glycation end product inhibitors. ( Grahovac, G; Kalluri, R; Sugimoto, H; Zeisberg, M, 2007) |
"Pyridoxamine treatment resulted in significantly lower (by approximately 50%) levels of urinary glycolate and oxalate excretion compared to untreated hyperoxaluric animals." | 1.33 | Pyridoxamine lowers kidney crystals in experimental hyperoxaluria: a potential therapy for primary hyperoxaluria. ( Belmont, JM; Chetyrkin, SV; Hudson, BG; Kim, D; Scheinman, JI; Voziyan, PA, 2005) |
Research
Studies (11)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (27.27) | 29.6817 |
2010's | 7 (63.64) | 24.3611 |
2020's | 1 (9.09) | 2.80 |
Authors
Authors | Studies |
---|---|
Kamphuis, JBJ | 1 |
Guiard, B | 1 |
Leveque, M | 1 |
Olier, M | 1 |
Jouanin, I | 1 |
Yvon, S | 1 |
Tondereau, V | 1 |
Rivière, P | 1 |
Guéraud, F | 1 |
Chevolleau, S | 1 |
Noguer-Meireles, MH | 1 |
Martin, JF | 1 |
Debrauwer, L | 1 |
Eutamène, H | 1 |
Theodorou, V | 1 |
Pereira, A | 1 |
Fernandes, R | 1 |
Crisóstomo, J | 1 |
Seiça, RM | 1 |
Sena, CM | 1 |
Illien-Junger, S | 1 |
Grosjean, F | 1 |
Laudier, DM | 1 |
Vlassara, H | 1 |
Striker, GE | 1 |
Iatridis, JC | 1 |
Elseweidy, MM | 1 |
Elswefy, SE | 1 |
Younis, NN | 1 |
Zaghloul, MS | 1 |
Dong, Z | 1 |
Iwata, D | 1 |
Kitaichi, N | 1 |
Takeuchi, M | 1 |
Sato, M | 1 |
Endo, N | 1 |
Iwabuchi, K | 1 |
Ando, R | 1 |
Fukuhara, J | 1 |
Kinoshita, S | 1 |
Lennikov, A | 1 |
Kitamura, M | 1 |
Mizuuchi, K | 1 |
Kanda, A | 1 |
Noda, K | 1 |
Namba, K | 1 |
Yamagishi, S | 1 |
Ohno, S | 1 |
Ishida, S | 1 |
Ren, X | 1 |
Sun, H | 1 |
Zhang, C | 1 |
Li, C | 1 |
Wang, J | 1 |
Shen, J | 1 |
Yu, D | 1 |
Kong, L | 1 |
Mori, Y | 1 |
Kakuta, T | 1 |
Miyakogawa, T | 1 |
Takekoshi, S | 1 |
Yuzawa, H | 1 |
Kobayashi, H | 1 |
Kawakami, A | 1 |
Miyata, T | 1 |
Fukagawa, M | 1 |
Jones, DC | 1 |
Alphey, MS | 1 |
Wyllie, S | 1 |
Fairlamb, AH | 1 |
Chetyrkin, SV | 1 |
Kim, D | 1 |
Belmont, JM | 1 |
Scheinman, JI | 1 |
Hudson, BG | 1 |
Voziyan, PA | 1 |
Coughlan, MT | 1 |
Cooper, ME | 1 |
Forbes, JM | 1 |
Sugimoto, H | 1 |
Grahovac, G | 1 |
Zeisberg, M | 1 |
Kalluri, R | 1 |
Reviews
1 review available for pyridoxamine and Disease Models, Animal
Article | Year |
---|---|
Can advanced glycation end product inhibitors modulate more than one pathway to enhance renoprotection in diabetes?
Topics: Animals; Diabetic Nephropathies; Disease Models, Animal; Glycation End Products, Advanced; Guanidine | 2005 |
Other Studies
10 other studies available for pyridoxamine and Disease Models, Animal
Article | Year |
---|---|
Lactose and Fructo-oligosaccharides Increase Visceral Sensitivity in Mice via Glycation Processes, Increasing Mast Cell Density in Colonic Mucosa.
Topics: Abdominal Oblique Muscles; Animals; Colon; Diet; Disease Models, Animal; Electromyography; Feces; Fe | 2020 |
The Sulforaphane and pyridoxamine supplementation normalize endothelial dysfunction associated with type 2 diabetes.
Topics: Animals; Aorta; Diabetes Mellitus, Type 2; Dietary Supplements; Disease Models, Animal; Endothelium; | 2017 |
Combined anti-inflammatory and anti-AGE drug treatments have a protective effect on intervertebral discs in mice with diabetes.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Diabetes Mellitus, Experimental; Disease Mo | 2013 |
Pyridoxamine, an inhibitor of protein glycation, in relation to microalbuminuria and proinflammatory cytokines in experimental diabetic nephropathy.
Topics: Albuminuria; Alloxan; Animals; C-Reactive Protein; Cytokines; Diabetes Mellitus, Experimental; Diabe | 2013 |
Amelioration of experimental autoimmune uveoretinitis by inhibition of glyceraldehyde-derived advanced glycation end-product formation.
Topics: Administration, Oral; Adult; Amino Acid Sequence; Animals; Autoimmune Diseases; Behcet Syndrome; Dis | 2014 |
Protective function of pyridoxamine on retinal photoreceptor cells via activation of the p‑Erk1/2/Nrf2/Trx/ASK1 signalling pathway in diabetic mice.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Disease M | 2016 |
Effect of Scavenging Circulating Reactive Carbonyls by Oral Pyridoxamine in Uremic Rats on Peritoneal Dialysis.
Topics: Administration, Oral; Animals; Dialysis Solutions; Disease Models, Animal; Kidney Failure, Chronic; | 2016 |
Chemical, genetic and structural assessment of pyridoxal kinase as a drug target in the African trypanosome.
Topics: Amino Acid Sequence; Animals; Antiprotozoal Agents; Disease Models, Animal; Enzyme Inhibitors; Gene | 2012 |
Pyridoxamine lowers kidney crystals in experimental hyperoxaluria: a potential therapy for primary hyperoxaluria.
Topics: Animals; Calcium Oxalate; Crystallization; Disease Models, Animal; Glyoxylates; Humans; Hyperoxaluri | 2005 |
Renal fibrosis and glomerulosclerosis in a new mouse model of diabetic nephropathy and its regression by bone morphogenic protein-7 and advanced glycation end product inhibitors.
Topics: Animals; Bone Morphogenetic Protein 7; Bone Morphogenetic Proteins; Diabetic Nephropathies; Disease | 2007 |